ESCC
Conditions
Keywords
Iparomlimab and Tuvonralimab Injection, Nab-Paclitaxel, neoadjuvant therapy, ESCC
Brief summary
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.
Detailed description
This clinical study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.This study consists of three phases: screening, treatment, and follow-up.Efficacy evaluation and safety monitoring should be performed throughout the study.
Interventions
DRUGlparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel
Iparomlimab and Tuvonralimab Injection: 5 mg/kg, q3w; Nab-Paclitaxel: 125 mg/m² on d1 and d8, q3w; Neoadjuvant therapy is administered for 4 cycles. The appropriate surgical timing will be determined by the physician based on the patient's condition, and surgery is scheduled for 4-6 weeks after the completion of neoadjuvant therapy.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntarily understand and sign the informed consent form for this study. * Age ≥ 18 years, male or female. * Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition). * ECOG performance status of 0-2. * No prior treatment for esophageal squamous cell carcinoma. * Life expectancy ≥ 3 months. * Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g/L; White blood cell count ≥ 3.5 × 10\^9/L; Absolute neutrophil count ≥ 1.5 × 10\^9/L; Platelets ≥ 80 × 10\^9/L; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL/min); Left ventricular ejection fraction (LVEF) ≥ 50%. * Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose.
Exclusion criteria
* Inability to comply with the study protocol or study procedures. * Presence of supraclavicular lymph node metastasis. * Obvious tumor invasion of organs adjacent to the esophageal lesion. * Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment. * Allergy or known hypersensitivity to the study drugs or their excipients. * Anticipated need for systemic corticosteroids or other immunosuppressive therapy during the study treatment period. * Active autoimmune disease requiring systemic treatment, or a history of autoimmune disease. * Positive HIV test; positive hepatitis B surface antigen with HBV-DNA \> upper limit of normal; active hepatitis C virus (HCV) infection. * History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before the first study drug administration; known severe varices on endoscopy within 3 months before the first study drug administration. * Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia that might interfere with the assessment and management of immune-related pulmonary toxicity. * Evidence of a significant bleeding tendency or other major coagulation disorders. * Severe cardiovascular or cerebrovascular disease. * Other malignancies within 5 years before enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. * History of allogeneic bone marrow transplantation or organ transplantation. * Patients considered by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic complete response rate (pCR) | up to 6 month | refers to the absence of viable tumor cells in both the primary tumor bed and the regional lymph nodes in the surgically resected specimens. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major Pathologic Response rate (MPR) | up to 12 month | — |
| R0 Resection rate | up to 12 month | — |
| Event-Free Survival (EFS) | up to 12 month | — |
| Disease-Free Survival (DFS) | up to 12 month | — |
| Overall survival | up to 36 month | Os was defined as the time from the first dose of study drug to death due to anycause. |
| Adverse Events | up to 36 month | An AE was defined as any untoward medical occurrence in a pharmaceutical productwhich does not necessarily have to have a causal relationship with this treatment. |
Countries
China
Contacts
CONTACTZhansheng Jiang, Doctor
CONTACTChang Liu
Outcome results
None listed